Disease-relevant cell-surface antigens (PolTREG CAR-Treg targets)

Disease-relevant cell-surface antigens recognized by PolTREG CAR-Tregs refer to a specific class of autoantigens targeted by PolTREG S.A.'s chimeric antigen receptor-engineered regulatory T-cell (CAR-Treg) therapies [1]. These antigens are typically tissue-specific proteins expressed in organs under autoimmune attack, such as myelin-associated proteins (e.g., Myelin Oligodendrocyte Glycoprotein or MOG) in the central nervous system for Multiple Sclerosis (MS) or islet-cell antigens for Type 1 Diabetes [2]. PolTREG's lead CAR-Treg candidate, PTG-007, is designed to recognize these antigens to facilitate the homing and localized activation of Tregs in MS patients [3]. Upon binding to the target antigen, the CAR-Tregs exert therapeutic effects by secreting anti-inflammatory cytokines like IL-10 and TGF-beta, which suppress pathogenic T-cell activity and promote immune tolerance [1, 4]. This targeted approach aims to treat neurodegenerative and autoimmune diseases without the broad immunosuppression associated with conventional therapies [2]. The specificity of these antigens is crucial for ensuring that the therapeutic effect is concentrated at the site of inflammation, improving safety and efficacy profiles compared to traditional treatments [1]. (Sources: [1] PolTREG S.A. Pipeline Overview, 2024; [2] Frontiers in Immunology, 'CAR-Treg cells in autoimmune diseases', 2023; [3] PolTREG Press Release on PTG-007, 2023; [4] Nature Reviews Neurology, 'Regulatory T cells in Multiple Sclerosis', 2022).

Other names

AutoantigensMyelin-associated antigensCNS-specific antigensIslet-specific antigensTissue-specific autoantigens

CAR-Tregs recognize these antigens via a chimeric antigen receptor (CAR), leading to localized activation and secretion of anti-inflammatory cytokines (e.g., IL-10, TGF-beta) to suppress autoimmune inflammation.